These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6688502)

  • 21. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute leukemia in patients treated for Hodgkin's disease].
    Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
    Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
    Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
    J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
    Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G
    J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
    Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
    J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities.
    Koziner B; Myers J; Cirrincione C; Redman J; Cunningham I; Caravelli J; Nisce LZ; McCormick B; Straus DJ; Mertelsmann R
    Am J Med; 1986 Jun; 80(6):1067-78. PubMed ID: 3755285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer.
    Carde P; Hayat M; Cosset JM; Somers R; Burgers JM; Sizoo W; Meerwaldt JH; Hagenbeek A; Monconduit M; van der Schueren E
    NCI Monogr; 1988; (6):303-10. PubMed ID: 3352775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
    Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
    Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease.
    Ekert H; Waters KD; Smith PJ; Toogood I; Mauger D
    J Clin Oncol; 1988 Dec; 6(12):1845-50. PubMed ID: 3058876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence.
    Khan SP; Gilchrist GS; Arndt CA; Smithson WA; Chen MG; Schomberg PJ; Matsumoto JM; O'Fallon WM
    Mayo Clin Proc; 1994 Oct; 69(10):949-54. PubMed ID: 7523802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty years of MOPP therapy for Hodgkin's disease.
    Longo DL; Young RC; Wesley M; Hubbard SM; Duffey PL; Jaffe ES; DeVita VT
    J Clin Oncol; 1986 Sep; 4(9):1295-306. PubMed ID: 3528400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The intergroup Hodgkin's disease in children. A study of stages I and II.
    Gehan EA; Sullivan MP; Fuller LM; Johnston J; Kennedy P; Fryer C; Gilchrist GS; Hays DM; Hanson W; Heller R
    Cancer; 1990 Mar; 65(6):1429-37. PubMed ID: 2407336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
    Blayney DW; Longo DL; Young RC; Greene MH; Hubbard SM; Postal MG; Duffey PL; DeVita VT
    N Engl J Med; 1987 Mar; 316(12):710-4. PubMed ID: 3821809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up.
    Olver IN; Wolf MM; Cruickshank D; Worotniuk V; Ding JC; Cooper IA; Matthews JP
    Cancer; 1988 Jul; 62(2):233-9. PubMed ID: 3383124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.